An anthraquinone compound of formula I (such as the compounds of formulae II to X) and processes for making the same are provided. Pharmaceutical compositions for use in the treatment of cancer, optionally in combination with an agent capable of reducing the level of oxygenation of a tumor, are also provided. Additionally, an option for combination with chemotherapeutic and radiotherapeutic modalities to enhance overall tumor cell kill is provided. Methods for the detection of cellular hypoxia, both in vivo and in vitro, are additionally provided. ##STR00001##

The invention provides branched trialkylamine oxides with improved properties. The trialkylamine oxides of the invention produced from branched trialkylamines, in one embodiment, can be made using certain branched C10-12 enals and aldehydes. The invention also provides an trialkylamine oxide having the formula:

##STR00001##

wherein R5, R6 and R7 are independently at least one of C3H7, C2H5, CH3, or H, or mixtures thereof; and wherein R5 and R6 are not H at the same time. In one embodiment, the trialkylamine oxides of the invention can be useful in making various products, for example, as surfactants.

The invention provides branched hydrophobes for the production of surfactants with improved properties over linear hydrophobes. The invention also provides branched C10-12 enals and aldehydes that are oxidized to branched fatty acids or hydrogenated to branched fatty alcohols and further derivatized to surfactants, through ethoxylation or esterification and other or subsequent reactions. The invention further provides surfactants made from the branched trialkylamine intermediates, including amphoteric, cationic and nonionic surfactants.

The invention provides branched hydrophobes for the production of surfactants with improved properties over linear hydrophobes. The invention also provides branched C.sub.10-12 enals and aldehydes. The invention additionally provides branched C.sub.10-12 enals and aldehydes that are oxidized to branched fatty acids or hydrogenated to branched fatty alcohols and further derivatized to surfactants, through ethoxylation or esterification and other or subsequent reactions. The enals and aldehydes are useful in making branched trialkylamine intermediates useful in making certain surfactants, including amphoteric, cationic and nonionic surfactants. The surfactants which can be produced from the trialkylamine intermediates include the quaternary ammonium compounds of the invention. The quaternary ammonium compounds of the invention are also useful in making the branched enals and/or aldehydes useful in the invention.

In certain aspects the methods comprise administering an inhibitor of hydrogen sulfide biosynthesis, a cystathionine--synthase (CBS) inhibitor, or a hydrogen sulfide neutralizing agent to a patient having a cancer associated with elevated production of hydrogen sulfide.

In certain aspects the methods comprise administering an inhibitor of hydrogen sulfide biosynthesis, a cystathionine--synthase (CBS) inhibitor, or a hydrogen sulfide neutralizing agent to a patient having a cancer associated with elevated production of hydrogen sulfide.

-Substituted -amino acids, -substituted -amino acid derivatives, and -substituted -amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the -substituted -amino acid derivatives and -substituted -amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

-Substituted -amino acids, -substituted -amino acid derivatives, and -substituted -amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the -substituted -amino acid derivatives and -substituted -amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that are suitable for diagnosis and the treatment of diseases and disorders characterized by, associate with or which exhibit tissue hypoxia, such as, for example, solid tumors. Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds.

Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that are suitable for diagnosis and the treatment of diseases and disorders characterized by, associate with or which exhibit tissue hypoxia, such as, for example, solid tumors. Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds.